Approved applications from the Breast Cancer Now Tissue Bank

Applications approved

To see papers published either about the Bank or the results of studies using samples from the Bank see the resources section.

Application title

Researcher, institution

Functional and translational implications of intragenic DNA methylation in breast cancer Dr James Flanagan, Imperial College London
Defining the male breast cancer genome Dr Valerie Speirs, Leeds Institute for Molecular Medicine
Is p52/Bcl3 activity associated with aggressive ER-negative breast cancer? Dr Richard Clarkson, Cardiff University
Locating the stem cell niche in the normal and hyperplastic human mammary gland Dr Stuart McDonald, Queen Mary and Westfield College, University of London
NMR-based metabolomics in the search for biomarkers of cancer occurrence and grade Dr Julie Fisher, University of Leeds
Investigating novel alternative splicing patterns in different breast tumours Dr Alison Tyson-Capper, Newcastle University
Identification of regulatory DNA variants in apoptosis genes associated with breast cancer risk Dr Sushilaben Rigas, University of Sheffield
Identification of targetable recurrent mutations and fusion genes in breast cancer subtypes Dr Rachael Natrajan, Institute of Cancer Research
Expression of voltage-gated sodium channel beta subunits in breast cancer Dr William Brackenbury, University of York
A new therapeutic target to facilitate radioiodine treatment of breast cancer Dr Vikki Poole, University of Birmingham
Regulation and function of p68 (DDX5)-drived long non-coding RNA and miRNAs in breast cancer Dr Frances Fuller-Pace, University of Dundee
Analysis of expression of Lyn kinase isoforms in breast cancer Dr Matthew Smalley, Cardiff University
Does b-variant Ciz1 have diagnostic or prognostic potential as a circulating biomarker for breast cancer? Dr Dawn Coverley, University of York
Investing the prognostic role of HER3 and HER4 expression and localisation in HER2-positive breast cancer Dr Anthony Kong, University of Oxford
Investing cancer-specific splicing in different breast tumours Dr Alison Tyson-Capper, Newcastle University
Developing patient-relevant models of breast cancer Dr Anna Grabowska, Nottingham University
Functional characterisation of male breast cancer susceptibility polymorphisms Dr Nick Orr, Institute of Cancer Research
The role of carbohydrate response element binding protein (IChREBP) in malignant progression and as a prognostic marker in breast cancer Dr Rachel Airley, University of Huddersfield
The role of nesprin/syne proteins in breast cancer development Dr Akis Karakesisoglou, University of Durham
Understanding the effects of oestrogen receptor binding and epigenetic remodelling in oestrogen receptor positive breast cancer Dr Darren K Patten, Imperial College of Science and Technology
Evaluation of extracellular matrix levels as biomarkers of response to
anti-HER2 therapy
Dr Paul Huang, Institute of Cancer Research 
Intra-tumour genetic heterogeneity of lymphocyte enriched triple-negative breast cancer Dr Rachael Natrajan, Institute of Cancer Research
Cancer testis antigen-derived T cell epitopes in triple negative breast cancers Dr Demin Li, University of Oxford
Exploration of a new biomarker to predict treatment response in basal-like breast cancer Dr Joanna Morris, University of Birmingham
Control of epithelial to mesenchymal transition by the miR-106b~25 cluster and EP300 in metaplastic breast cancer Dr Ernesto Yague, Imperial College of Science and Technology 
Identification of biomarkers to predict response to standard of care DNA damaging chemotherapy in triple negative breast cancer Niamh Buckley, Queen's University Belfast
Determination of the importance of transcriptional drivers in breast cancer development, progression and response to targeted therapeutic agents Professor Simak Ali, Imperial College London